focus -WSS

focus

author：comprehensive 2025-10-04 05:37:35 Page View：3619

U.S. President Joe Biden stands with his fingers locked next to an US flag — politics coverage from STAT — President Biden's White House on Monday ballyhooed a routine step in Medicare’s new program to negotiate the prices of prescription drugs.

WASHINGTON — The White House on Monday ballyhooed a routine step in Medicare’s new program to negotiate the prices of prescription drugs, its latest effort to draw attention to the program in an election year.

The news is not controversial: The pharmaceutical companies that make the first ten drugs up for negotiation all submitted counteroffers. It’s an incremental step in the new program, which was created in 2022.

Earlier this year, Medicare sent its initial price offers to the companies. Neither the Biden administration nor the drug manufacturers have volunteered any information about the White House’s initial price offers or the counteroffers. The process is scheduled to end by Aug. 1.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Why scientists need input from humanists on sensitive research
Next article： Novavax promises a turnaround & Lilly roils the obesity market

comprehensive

ChatGPT in medicine: STAT answers readers' burning questions

MikeReddyforSTATArtificialintelligenceisoftendescribedasablackbox:anunknowable,mysteriousforcethatop

Intermittent fasting comes with a heart risk? Not so fast

AdobeThenewsiseverywhereinmysocialnewsfeedsthismorning:Apopularfaddietisapparentlylethal,scientificr

Moonlake's readout produced a cash windfall. Risks remain

MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

First U.S. drug developed to treat liver disease MASH is approved

AdobeTheFoodandDrugAdministrationonThursdayapprovedthefirstmedicinedevelopedspecificallytotreatthese

focus

explore

comprehensive

First U.S. drug developed to treat liver disease MASH is approved